Protia Inc. has set a new benchmark in equine diagnostics with its groundbreaking ANITIA Equine IgE allergy testing kit, offering unprecedented accuracy, efficiency, and convenience in identifying and managing allergies in horses.
Protia Inc., an innovator in diagnostic medical devices, has unveiled its latest groundbreaking development in equine healthcare—the ANITIA Equine IgE allergy testing kit. Billed as the most extensive equine allergy diagnostic tool globally, this kit is designed to revolutionize the way veterinarians identify and manage allergic conditions in horses. Protia’s advanced solution simplifies the process of diagnosing allergies, offering increased accuracy and a streamlined approach compared to traditional methods. The ANITIA Equine IgE kit can detect up to 120 different allergens, including vegetation, pollen, molds, mites, insects, and more. It can detect a higher number of allergens compared to other existing equine allergy diagnostic products.
With allergies presenting a common yet complex challenge in equine health, Protia’s innovation is both timely and essential. Horses often suffer from environmental and dietary allergens, which can lead to conditions such as atopic dermatitis or insect-induced hypersensitivity. The ANITIA Equine IgE kit utilizes state-of-the-art immunoblot technology to detect allergen-specific IgE antibodies in equine serum, promising a less invasive and more reliable alternative to skin tests.
The ANITIA Equine IgE allergy testing kit debuted at the American Association for Diagnostic Laboratory Science (ADLM) exhibition in Chicago in July and exhibited its products at MEDICA. Protia plans to expand its reach to 14 key international markets, including Europe, China, and Japan, as well as emerging markets in Asia-Pacific, South America, and the Middle East. However, specific timelines for availability in these regions have not been disclosed yet.
READ our articles on veterinary medicine.
Advanced Methodology: Simplifying Complex Diagnostics
The ANITIA Equine IgE kit incorporates a unique multiplex immunoassay system, enabling simultaneous detection of up to 120 allergens. The test panels include a variety of environmental allergens like pollen, molds, and insect proteins, as well as dietary substances. By employing a nitrocellulose membrane with parallel allergen arrays, the kit increases efficiency, allowing a single test to provide comprehensive insights.
A highlight of the test’s design is its flexibility: it can be performed manually, semi-automatically, or fully automatically using Protia’s proprietary devices like the Q-Smart (V) and Q-STATION ELITE (V). Results, quantified in allergen-specific AU/mL, are easy to interpret, offering a clear grading system from weak to strong IgE responses. This ensures a precise diagnostic workflow while minimizing human error and operational time. Additionally, the kit demonstrates impressive sensitivity with a detection limit of 0.30 AU/mL, making it a reliable tool for veterinarians.
FIND testing kits on MedicalExpo.
Economic Impacts and Clinical Implications
The launch of this advanced diagnostic tool aligns with the expanding global equine healthcare market, which is projected to grow significantly in the coming decade. Protia’s kit not only serves the high-end horse industry but also facilitates cost-effective diagnostics for equestrian sports, leisure, and breeding programs. By streamlining allergy identification, the kit supports better-targeted treatments, ultimately improving the quality of life and performance of horses.
Protia has leveraged its expertise in companion animal diagnostics to meet the specific needs of equine practitioners. In doing so, it addresses an economic gap, offering a tool that balances precision and accessibility. The kit also emphasizes the importance of proactive healthcare by identifying allergens early, reducing the need for costly treatments associated with prolonged allergic conditions.
International Rollout: Protia’s Global Vision
Building on its established market presence in canine and feline diagnostics, Protia is targeting major equine markets, including the U.S., Europe, and Asia-Pacific regions. The kit’s debut at the American Association for Diagnostic Laboratory Science (ADLM) exhibition signals the company’s commitment to innovation and global outreach. With plans for a phased rollout and regional partnerships, Protia is poised to address growing demands in emerging markets as well.
The company is prepared to meet these demands through scaled-up production and advanced logistical networks, ensuring timely delivery and widespread availability. Veterinarians attending the ADLM event will have the opportunity to witness live demonstrations, emphasizing the ease of integrating the ANITIA Equine IgE into their practices.
Protia’s focus on seamless diagnostic solutions underscores its dedication to advancing veterinary medicine, setting a new benchmark in equine healthcare. The ANITIA Equine IgE testing kit represents a transformative step forward, combining technological innovation with clinical utility to improve outcomes for horses worldwide.
